CJC-1295
GHRH analogue + ghrelin mimetic, the GH stackGrowth-hormone-releasing therapy to support your body’s own GH pulses, sleep, recovery, and body composition, monitored against your labs.
CJC-1295 raised GH secretion up to five-fold in early clinical studies, by amplifying your own nightly pulses rather than replacing them. Long-term outcome evidence is limited, and your consultant will be direct about what is and isn’t established. Full reference →
Who this is for
Adults with declining recovery, sleep quality, or body composition where labs support GH-axis therapy. Candidacy is decided with your consultant against your history and IGF-1, never by a checkout flow.
How the program works
Your consultant goes through your goals, history, and whether this therapy is appropriate. If it isn't, you'll hear that instead.
An at-home blood draw establishes your baseline. Your pen ships cold-chain once your program is agreed.
A small dose before bed, timed to your natural GH pulse. Video review at week 6, messaging in between.
IGF-1 and symptoms reviewed against baseline. Together you decide: continue, adjust, or taper off with a plan.
Common questions
Sleep depth often shifts within weeks; body-composition changes are slower and tracked at your IGF-1 reviews. Your consultant measures rather than promises.
No. CJC-1295 and Ipamorelin prompt your pituitary to release its own GH in natural pulses. Levels stay within physiological rhythm and are checked against IGF-1, which is a different risk profile from injecting GH itself.
Your program is quoted in full after your consultation, before anything is supplied. There is no set program price because there is no off-the-shelf product: dose, timing and monitoring differ per patient.
The CJC-1295 and ipamorelin combination pairs two research peptides that engage parallel growth-hormone-axis pathways. CJC-1295 is a synthetic GHRH analog. Ipamorelin is a selective growth hormone secretagogue. The two compounds bind different receptors (GHRH receptor and GHSR-1a respectively) and converge on growth hormone release through distinct upstream pathways.
Raun and colleagues (Eur J Endocrinol, 1998) characterised ipamorelin as the first growth hormone secretagogue that releases GH without significantly elevating ACTH or cortisol, in contrast to earlier secretagogues like GHRP-2 and GHRP-6 which trigger broader pituitary hormone release. The selectivity refers to the relative specificity for the GH axis rather than to receptor selectivity (ipamorelin binds GHSR-1a, the same receptor as ghrelin).
No. Neither CJC-1295 nor ipamorelin has marketing authorisation as a pharmaceutical in any jurisdiction. Both are supplied as research peptides for laboratory use only. The published evidence base for CJC-1295 includes Phase 1 healthy volunteer trials (Teichman 2006). Ipamorelin has been studied across preclinical and early-phase human work but has not progressed to approval.
Two routes to the same axis
CJC-1295 is a synthetic analog of the first 29 amino acids of native GHRH (GRF 1-29), with stabilising amino-acid substitutions at positions 2, 8, 15, and 27 to extend serum half-life relative to native GHRH. The compound binds the growth hormone releasing hormone receptor on anterior pituitary somatotroph cells and stimulates pulsatile GH release.
Ipamorelin binds the growth hormone secretagogue receptor (GHSR-1a, the ghrelin receptor) and stimulates GH release. Unlike earlier GH secretagogues, ipamorelin has minimal effect on ACTH or cortisol release (Raun et al, Eur J Endocrinol, 1998;139(5):552-561), giving it the "selective" designation.
CJC-1295 acts at the GHRH receptor. Ipamorelin acts at the growth hormone secretagogue receptor. The two receptors trigger GH release through distinct upstream pathways that converge on the somatotroph. Combination protocols are used to probe synergistic activation of GH secretion via parallel pathway engagement.
CJC 1295 is also searched as Mod GRF 1-29, CJC1295, Ipamorelin.